In addition to developing their lead asset, the Nu-3 gel in iDFU, Lakewood-Amedex is continuing to explore new, very potent molecules that have been recently discovered. The key focus of the discovery effort is to match the molecular properties of the newly discovered compounds to potential indications. The BisphosphocinTM class and the newly discovered compounds have molecular properties that allow for a broad range of different formulations to be developed including solutions, gels, nasal sprays, and nebulizers. The indications being explored include complicated urinary tract infections via catheter delivery, envelope virus infections via nasal spray, bacterial lung infections including Community and Hospital Acquired Bacterial Pneumonia (CABP & HABP) via nebulizer, Cystic Fibrosis via nebulizer, and wound infections such as Methicillin Resistant Staphylococcus aureus (MRSA), surgical infections, and atopic dermatitis via gels.
Lakewood-Amedex’s broad antimicrobial technology platform is well protected by an intellectual property portfolio. The broad patent estate comprises 86 patents, 27 of which have been allowed, with the remaining 59 being pending applications. The key patent filings protect through to at least 2038.